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Thisreviewwillbrieﬂydescribeintegrinfunction,addresswhyintegrinsareattractivetargetsforchemotherapeuticdrugdesign,and
discuss some ongoing studies aimed at inhibiting integrin activity. Integrins are cell surface heterodimeric receptors. They modulate
many cellular processes including: growth, death (apoptosis), adhesion, migration, and invasion by activating several signaling
pathways. Many potential chemotherapeutic agents target integrins directly (eg, polypeptides, monoclonal antibodies, adenovirus
vectors). These agents may be clinically useful in controlling the metastatic spread of cancer.
INTRODUCTION
The primary therapy for most solid tumors is surgi-
cal resection, followed by a combination of radiation and
chemotherapy. Most of the currently used chemotherapeu-
tic agents target the rapidly dividing cells. However, many
solid tumors are not rapidly dividing and thus evade these
agents. Often, tumors that resist or evade chemotherapy
treatments continue to grow, and may spread to other, dis-
tant organs, resulting in the formation of secondary tu-
mors (metastases). Once a cancer develops to this stage, pa-
tient prognosis is usually very poor. Novel chemotherapeutic
agents need to be developed to help control the growth and
spread of metastatic tumors. In this review, we discuss the
potential value of integrins as chemotherapeutic targets. The
function of integrins in cancer progression is addressed, fol-
lowed by a discussion of current drug discovery eﬀorts and
clinical trials of compounds that speciﬁcally target integrin
receptors.
The latest generation of chemotherapeutic agents is de-
signed to target molecules required for survival by cancerous
cells but not by normal cells. One very interesting group of
moleculesthatarereceivingattentionistheintegrinfamilyof
cellsurfaceadhesionreceptors.Inthepasttenyears,ithasbe-
come clear that the integrins play an important role in virtu-
ally every stage of cancer progression. In addition, oncogenic
transformation is often accompanied by changes in integrin
expression and substrate preference. Although integrins are
notoncoproteins,theymodulatetheprocessesofcellgrowth,
death, migration, and invasion, which all impinge on the
severity of clinical disease [1]. Several drugs in clinical trials
function as integrin antagonists; all having shown promise
as antiangiogenic, antimetastatic, and antiproliferative com-
pounds in mouse models [2].
INTEGRIN STRUCTURE AND FUNCTION
Integrins are a family of heterodimeric cell surface recep-
tors. The known 18 α and 8 β subunits combine to form at
least 24 αβ heterodimers (for recent reviews see references
[2, 3, 4]). Most cells express more than one type of integrin
heterodimer. Integrin expression proﬁles are unique for dis-
tinct cell types, and change with developmental stage and
physiological conditions within a cell type [5]. Most inte-
grins mediate cell/substratum adhesion by binding to extra-
cellular matrix (ECM) proteins, while a few mediate cell-cell
adhesion via homotypic or heterotypic coupling with other
cell surface receptors. This family of receptors can be clas-
siﬁed into three subfamilies. The β1 integrins generally me-
diate interactions between cells and ECM. The β2 integrins
are restricted to leukocytes and are typiﬁed by having other
cell surface proteins as their ligands. The β3 integrins are al-
most exclusively expressed on platelets and megakaryocytes
and act as important mediators of platelet adhesion [6]. Ex-
cepting the ﬁbronectin receptor α5β1, all integrins bind to
more than one ligand. Each ECM molecule is also bound by
more than one integrin. Although it is impossible to predict
an integrin binding site based on sequence, an acidic residue
is common to all known binding sites, and many contain the
sequence RGD [2].
At sites of integrin activation and clustering, protein ag-
gregates termed focal complexes and focal adhesions assem-
ble on the intracellular surface. The types of proteins that
form these complexes can be grouped as either structural,
which form links to the actin cytoskeleton, or signaling,
which include a variety of kinases and adapter molecules
linking integrins to other kinases, members of the GTPase
families, lipid kinases and phospolipases, and ion chan-
nels [7, 8]. The structural components are talin, α-actinin,2:3 (2002) Integrin Receptors: Unrealized Chemotherapeutic Targets 125
vinculin, and ﬁlamin. Of these, only α-actinin binds di-
rectly to integrins, while the others are capable of binding
each other and members of the signaling component [9, 10].
These complexes are sites where the cell can generate tension
with respect to its surroundings, allowing the cell to alter its
shapeandcarryoutcomplexprocessessuchasmigrationand
cell division [2].
INTEGRIN CLUSTERS ARE SIGNALING COMPLEXES
The signaling proteins found at focal complexes and fo-
cal adhesions associate with integrin cytoplasmic domains to
form a nexus for stimulating intracellular signaling cascades.
At these sites, signaling from outside to inside the cell occurs,
which contributes to the regulation of diverse cellular pro-
cesses including entry into the cell cycle, programmed cell
death (apoptosis), gene transcription, regulation of intracel-
lular pH, diﬀerentiation, and migration. A summary of the
known signaling pathways associated with integrin receptors
ispresentedinFigure 1.Signalingthroughintegrinsfromthe
inside to the outside of the cell regulates adhesive strength
through aﬃnity and avidity modulation, and helps in the
remodeling of the ECM during tissue development and tis-
sue invasion. Exactly how this occurs is unknown, but phos-
phorylation of integrin subunits may be important in both
processes [6].
The 125kda kinase termed focal adhesion kinase (FAK)
is the best characterized of the integrin-associated signaling
proteins. FAK binds to integrin receptors and plays a cen-
tral role in assembling complexes of signaling proteins at the
cell surface. FAK has numerous tyrosine residues that, when
phosphorylated, act as docking sites for the recruitment and
activation of several SH2- and SH3-containing classes of sig-
naling molecules. Talin and paxillin are implicated in the ac-
tivation of FAK by stimulating its autophosphorylation on
Y397. This opens a binding site for the oncoprotein Src. All
three of these molecules are implicated in targeting FAK to
the focal adhesion. Src also phosphorylates FAK on a num-
ber of residues, including Y925. The adaptor protein Grb2
binds to phosphorylated Y397, and through the action of
the guanine nucleotide exchange factor SOS, connects ac-
tivated receptor tyrosine kinases to Ras/ERK/MAP kinase
cascades, [2, 4, 8, 11]. Phosphatidyl Inositol 3-Kinase (PI-
3K) also binds to Y397, and mediates cell proliferation, cell
migration, and apoptosis through its downstream eﬀector
PKB/Akt [3, 5]. The adaptor protein p130CAS is a substrate
of the FAK/Src complex and is implicated in activating the
ERK cascade as well as Jun N-terminal kinase (JNK). Both
p130CAS and FAK are thought to use the ERK pathway to ac-
tivateseveraltranscriptionfactors[4]. FAK is also implicated
incontrollingcellcycleprogressionandpreventingapoptosis
throughapathwayinvolvingproteinkinaseC,phospholipase
A2, and p53 [4, 12].
Integrin regulated signaling proteins that can be acti-
vated independently of FAK include protein kinase C, in-
tegrin linked kinase, integrin associated protein, and the
tetraspan (TMS4F) adapter proteins [2, 11]. Integrin linked
kinase appears to phosphorylate only integrin subunits, and
may function as a bridge to FAK [2]. Although tetraspans
can regulate cell motility, their mechanism of action is not
understood.
INTEGRINS CONTRIBUTE TO CANCER PROGRESSION
Integrins act to promote the growth, and retard the
death, of both normal and tumorigenic cells. In cooperation
with growth factor receptors, they induce proliferation by
speciﬁcally causing the transcription of the cyclins and cyclin
dependent kinases (Cdks) required for transition past the
G1 checkpoint, and by down-regulation of Cdk inhibitors
[2, 6, 12]. The fact that most cells deprived of ECM in-
teractions undergo apoptosis (programmed cell death), and
that integrin ligation can rescue those cells, demonstrates
thatintegrinsareinvolvedinstimulatingapoptosisresistance
mechanisms[2].Forinstance,insomecelllines,integrinsac-
tivatetranscriptionoftheBcl-2geneandincreasetheactivity
of MAPK, JNK, PI-3 kinase, and PKB/Akt, all of which are
known to inhibit apoptosis [2, 3, 5, 6]. Lastly, cell death by
deprivation of engagement of ECM (anoikis) may be an im-
portant control mechanism in cancer since carcinoma cells
that lose contact with the matrix would die rather than cir-
culate and colonize distant sites [3, 5]. Hence, changes in the
integrin expression proﬁles may dramatically inﬂuence the
progression of malignant tumors.
Benign tumors are encapsulated by an organized lattice
ofbasementmembranecomponents.Theprogressiontoma-
lignancy, and the clinical diagnosis of malignant disease, is
essentially determined by the capability of tumor cells to dis-
sociate,degradethelattice,andmetastasizetootherlocations
within the body. This process, termed the metastatic cascade,
begins with the detachment of single tumor cells and active
inﬁltration of those cells into the surrounding stroma where
entry into the vasculature and lymphatic system is possible.
Dissociation of individual cells from a tumor mass is regu-
lated by the E-cadherin family of receptors. These are shown
to be suppressors of epithelial tumor metastasis. Recently,
activation of integrin α3β1 was shown to down-regulate E-
cadherin mediated adhesion, causing loss of cell-cell adhe-
sion,junctionalcommunication,andenhancinginvasiveness
of malignant tumor cells [13]. For invasion by dissociated
cells to occur, the ECM that surrounds the neoplastic tissue
must be degraded to allow the escape of invasive cells. Inte-
grins participate in the ECM degradation by stimulating the
secretion of ECM-degrading proteases such as matrix metal-
loproteases, and enhancing invasion through a signaling cas-
cade involving Ras [2, 3].
INTEGRINS AS THERAPEUTIC MARKERS
The large number of investigations into the eﬀective-
ness of integrins as indicators of disease and as an aid to
noninvasive cancer imaging underline the potential useful-
ness of these receptors in the clinic. Several recent stud-
ies show that both up-regulation and down-regulation of126 William L. Rust et al 2:3 (2002)
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Figure 1. Schematic of known integrin-associated signaling pathways. Solid arrows indicate direct association between signaling partners, while dashed
arrows indicate associations that may involve the action of unidentiﬁed intermediates. Abbreviations: CAMKII, Calmodulin dependent protein kinase II;
CAS, Crk-associtaed substrate; FAK, focal adhesion kinase; JNK, Jun kinase; Myosin Light Chain-P, phosphorylated myosin light chain; PI3K and PI4K,
phosphatidyl inositol 3 (or 4) kinase; PKC, protein kinase C; TM4SF, tetraspan superfamily of proteins.
integrin expression can be eﬀective markers of incidence
of disease and patient prognosis. A comparison of nor-
mal and neoplastic human prostate tissues showed a down-
regulation of a speciﬁc variant of the β1 integrin subunit
[14], and strong evidence shows that reduced expression
of α6a n dβ4 may contribute to the higher tumorigenic-
ity of androgen-independent prostate tumor cells [15]. In a
study of metastatic melanoma, longer disease free survival
and overall survival correlated with β1 expression [16], while
neuroblastomaaggressivenesswascorrelatedwithexpression
of integrin αvβ3a n dαvβ5 by the microvascular endothe-
lium[17].Studiesofacutelymphoblasticleukemiashowthat
β2 expression was signiﬁcantly associated with splenomegaly
[18], and expression of α5β1 was associated with positive re-
sponse to chemotherapy in patients with rectal cancer [19].
Finally, node negative nonsmall cell lung cancer patients2:3 (2002) Integrin Receptors: Unrealized Chemotherapeutic Targets 127
w h o s et u m o r so v e r - e x p r e s si n t e g r i nα5h a dal o w e rs u r v i v a l
rate than those whose did not [20].
These clinical correlations of patient biopsies to integrin
expression are recapitulated to some degree in rodent and in
vitro analyses. For example, a study of rat hepatocarcinogen-
esis showed that integrins α1a n dα5 were up-regulated in
metastases of the lung and diaphragm, while integrins α1,
α2, α3, and α5 were decreased in the primary carcinoma
and preneoplastic nodules [21]. Among pancreatic cancer
cell lines, those that showed a higher potential to metasta-
size in a mouse model had enhanced the expression of αvβ5
while those that did not metastasize had enhanced expres-
sion of α3[ 22]. The expression of β4 was inversely correlated
with dissemination of ten human gastric cancer cells lines in
SCID mice [23], and two of three human epithelial ovarian
cancer cell lines could be identiﬁed by the high expression of
αvβ6 integrin, which was correlated with integrin-linked sig-
naling and protease secretion [24]. The development of en-
dometrial cancers has been linked to the loss of progesterone
receptors. It was found that re-expressing an isoform of that
receptor inhibited both the expression of integrin subunits
α3, β1, and β3, and inhibited cell invasion into matrigel [25].
In addition to the cases mentioned above, integrin ex-
pression can also be speciﬁc to levels of tumor resistance to
common anticancer chemotherapies. Gastrointestinal tumor
cells selected for resistance to 5-ﬂuorouracil showed marked
under-expression of the integrin α3[ 26], while human ovar-
ian cancer cell lines resistant to the fenretinide were associ-
ated with reduced expression of β1 integrin [27]. A nasal car-
cinoma cell line resistant to melphalan showed increased ex-
pressionofα2,α5,α6,andβ4,decreasedexpressionofα4and
exhibited enhanced invasion in vitro [28]. Glioma cell lines
resistant to vincristine, doxorubicin, and etoposide showed
enhanced expression of integrins α2, α3, α5, and β1[ 29].
If the integrin receptors expressed by a particular tu-
mor are reproducibly correlated with patient prognosis, that
knowledge can be used by the clinician to choose the appro-
priate therapeutic regimen. Noninvasive imaging based on
integrin expression is potentially useful not only to identify
particular types of tumors but also to assess their responsive-
ness to particular drugs or drug-targeting methods. In two
recent studies, a glycopeptide containing the integrin bind-
ing domain RGD was found in tumor mouse models to be
suitable for tumor visualization and determination of inte-
grin status [30], and a similar peptide speciﬁcally bound to
αvβ3 expressing tumors in vivo [31].
INTEGRINS AS TARGETS FOR DRUG DELIVERY
AND GENE THERAPY
Achieving tissue-speciﬁc drug delivery is the primary
challenge faced by researchers in the ﬁelds of gene ther-
apy, targeted drug delivery, and immune meditated tumor
destruction. Integrin expression can both provide solutions
to and exacerbate the diﬃculty of this problem. An excel-
lent example is the use of recombinant adenoviruses that
interact with cell surface integrins. Some adenoviruses are
successfullyinternalizedintohostcellsbyformingcomplexes
withthehostproteinsCAR(CoxsackieBvirusandAdRecep-
tor) and integrins αvβ3a n dαvβ5[ 32]. The semispeciﬁc ex-
pression of these proteins makes targeting diﬃcult. In some
cases, replacing the binding capacities of the viral capsid may
prove to be eﬀective, while in others it may be eﬀective to en-
hancetheintegrinbindingcapacities.Usingtheformerstrat-
egy,anadenoviralvectortargetedsolelytothehumanepider-
mal growth factor receptor showed improved targeting to tu-
mors of the brain [33]. But an adenovirus vector targeted to
CAR, epidermal growth factor receptor, and αv integrins via
the RGD peptide showed enhanced gene transfer eﬃciency
to pancreatic carcinoma and glioma cells [34, 35]. In a study
of adenoviral gene transfer eﬃciency in ovarian cancer cells,
poorly infected cell lines showed no expression of αvβ3 in-
tegrins, and re-expression of these receptors increased aden-
oviral infection [36]. In order to target cells not expressing
CAR nor αv integrins, an antibody speciﬁc for the adenovi-
ralvectorwasfusedwithrecombinantgrowthfactorstoserve
as a bridge for targeted infection [37]. Recently, integrin re-
ceptors expressed in large numbers on most ovarian cancers
(αvβ3a n dαvβ5) were used as binding targets for adenovirus
vectorscontainingtheherpessimplexvirusthymidinekinase
gene for molecular chemotherapy [38]. These vectors were
very eﬀective against puriﬁed primary ovarian cancer cells
and may be a useful agent for treating ovarian cancer in clin-
ical trials.
Another example is the targeting and activation of lym-
phoid cells to tumor sites, which depend upon binding to in-
tegrin receptors. This binding can be modulated by secreted
chemokines [39]. In a unique mixture of strategies, infection
of mice with adenovirus carrying IL-12 gene and targeted to
αvβ3 integrin expressed on liver metastases led to enhanced
recruitment of adoptively transferred cytolytic T lympho-
cytes [40]. In another case, a human transitional cell carci-
noma cell line transfected to over-express IL-6 showed con-
comitant increases in α5a n dβ1 expression, which increased
the adherence of tumor destroying cells of bacillus Calmette-
Guerin therapy [41]. A chimeric cell adhesion molecule con-
taining the αvβ3 disintegrin kistrin and CD31/PECAM-1
served as a bridge to home adoptively transferred lymphoid
cells to angiogenic endothelial cells and caused the accumu-
lation of lymphoid cells to angiogenic tumors in Lewis lung
and melanoma mice models [42].
Finally, in an eﬀort to target a recombinant virus that
doesnotuseintegrinsintheprocessofinternalization,acap-
sid of the feline panleukopenia virus was modiﬁed to express
the RGD motif to bind αv integrins. This successfully con-
tributed to directing infection of those particles to a human
rhabdomyosarcoma cell line [43].
NONVIRAL STRATEGIES FOR DISRUPTING INTEGRINS
Nonviral and nonlymphoid strategies for integrin-
speciﬁc tumor targeting focus on integrin-speciﬁc antibod-
ies, soluble integrin ligands, or vectors that encode cyclic gly-
copeptides that contain the integrin binding RGD sequence.128 William L. Rust et al 2:3 (2002)
A vector with the RGD motif was found to preferentially
colocalize to tumor tissues over the lung, kidney, and spleen
in nude mice [44]. In lysosomal vectors that resemble retro-
viral envelopes but are not-toxic, this motif was shown to aid
transduction of human melanoma cells [45]. The antimicro-
bial peptide tachyplesin coupled to this motif was eﬀective in
inhibiting the growth of tumors in a mouse model and in-
ducing apoptosis of prostate cancer cells in vitro [46]. Alone,
an RGD containing peptide caused anoikis of glioblastoma
cell lines and prolonged the survival of SCID mice with in-
tracranialtumors[47].Andﬁnally,RGDcontainingpeptides
have shown promise as drug delivery agents for radiother-
apy. This is thought to be eﬀective because irradiated tumor
blood vessels are found to have activated αIIbβ3 integrins. At
least one of these peptides, biapcitide is currently in clinical
trials [48].
Disintegrin is the name given to soluble integrin lig-
ands(originallyisolatedfromsnakevenom)thatdisruptcell-
matrix interactions [49]. One disintegrin, contortrostatin,
disrupts cytoskeletal structure and hence inhibits cell motil-
ity, raising the possibility that these compounds may be
useful for therapeutic intervention for cancer invasion and
metastasis [50].
Abciximab is a mouse-human chimeric monoclonal Fab
fragment approved for adjunct therapy for the prevention of
cardiac coronary intervention. Abciximab binds to the inte-
grinαIIbβ3(GPIIbIIIa)receptoronplatelets,whichisthema-
jor adhesion receptor involved in aggregation. It also binds
two other integrin receptors: the αvβ3r e c e p t o r( p r e s e n ti n
high density on activated endothelial and smooth muscle
cells) and αMβ2 integrin (present on activated leukocytes)
[51]. It is reasonable to assume that Abciximab may have
antimetastatic properties in cases of tumors that express the
above integrin receptors.
The speciﬁcity of these inhibitors varies for diﬀerent
types of integrins. Therefore, to develop and then eﬀectively
utilize an anti-integrin therapy, the type of integrin and/or
eﬀectiveness of each agent or combination of agents must
be measured. We have developed a ﬂuorescence-based auto-
mated assay for identifying antimigratory compounds with
the ability to discern cytotoxic from noncytotoxic modes
of action that can achieve this goal [52]. The assay uti-
lizes a chambered well that can be used to simultaneously
measure migration and viability of cells following treatment
with inhibitors. This enables us to assay the eﬀects of com-
pounds that disrupt integrins directly, or that interfere with
downstream signaling events following integrin ligation. For
example, with this assay we have been able to show that
carboxyamidotriazole, a calcium channel blocker, inhibits
chemotactic and haptotactic migration of breast cancer cells
more eﬀectively than tamoxifen (an antiestrogen). This assay
shouldincreasetheabilitytorapidlyscreenchemicallibraries
for even more compounds that inhibit integrin function.
These are but a few examples of agents currently in de-
velopment to target integrins as anticancer therapies. These
agents hold the promise of being eﬀective, selective, and
highly tolerable in adjuvant therapies.
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